Antiangiogenic immunotherapy benefits from targeting antigens expressed on genetically stable endothelial cells and represents a novel modality for cancer treatment. Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2, also known as flk1 in mouse) mediated VEGF signaling is the key rate-limiting step in angiogenesis. Blockade of the flk1 signaling pathway can significantly inhibit tumor cell-induced angiogenesis and lead to inhibition of tumor metastasis. Interferon-gamma (IFN-g) is a pleiotropic cytokine, which plays an important role in cell-mediated immunity. In this study, we tested the hypothesis that immunization of mice with soluble flk1 (sflk1) and IFN-g fusion gene-transfected dendritic cells (DC-sflk1-IFN-g) would induce a potent CTL response to flk1, leading to an inhibition of tumor-induced angiogenesis and metastasis. Our data show that immunization of mice with sflk1 gene-modified DC (DC-sflk1) could induce a CTL response to flk1, leading to profound inhibition of tumor-cell-induced angiogenesis and metastasis. However, more striking antimetastatic effects were achieved through induction of enhanced CTL response to flk1 and augmented inhibition of angiogenesis when mice were immunized with DC-sflk1-IFN-g. In vivo T-cell subset depletion experiments showed that CD8 + T cells were mainly responsible for this antimetastatic effect. Our data extend the notion that DC-based active antiangiogenic immunotherapy is an effective modality for cancer treatment, and show that the antitumor efficacy of this strategy can be improved by combination with DC-based cytokine immunotherapy. Gene Therapy (2005) 12, 742-750.
Introduction
Tumor angiogenesis, that is, formation of new vessels supplying the tumor mass, is critical for tumor progression, outgrowth, and metastasis because all tumors beyond a minimal size of 0.5-2.0 mm require blood supply. [1] [2] [3] Many molecules have been demonstrated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-a, TGF-b, hepatocyte growth factor, TNF-a, angiogenin, IL-8, and angiopoietins. However, vascular endothelial growth factor (VEGF) signaling through its receptors often represents a crucial ratelimiting step in angiogenesis. 4 VEGF receptor 2 (VEGFR2), also known as fetal liver kinase 1 (flk1) in mouse and kinase insert domaincontaining receptor (KDR) in human, is strongly implicated as a therapeutic target as it is strictly expressed on endothelial cells and upregulated once these cells proliferate during angiogenesis in the tumor vasculature. Furthermore, VEGFR2 serves as the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF. [2] [3] [4] [5] [6] In the past, several approaches have been used to block flk1 signaling in the antiangiogenic therapy for cancers, including dominant-negative receptor mutants, 7 neutralization of VEGF by monoclonal antibodies, 8 administration of xenogeneic endothelial cells, 9 and vaccination with attenuated Salmonella typhimurium expressing VEGFR2 cDNA. 10 Very recently, it has been demonstrated that active immunization with soluble flk1 (sflk1) protein-pulsed dendritic cells (DC) 11 and VEGFR2-encoding mRNA transfected DC 12 can break self-tolerance to flk1 and inhibit tumor-induced angiogenesis, leading to inhibition of tumor growth and metastasis.
Interferon-gamma (IFN-g), a product of Th1, CTL, and NK cells, is one of the major effector molecules in cellmediated immunity. [13] [14] [15] [16] It plays important roles in the induction of CTL and differentiation of Th1 cells by increasing the expression of MHC class I and II and contributing to efficient antigen presentation to lymphocytes. IFN-g treatment instructs myeloid DC to develop into mature DC with increased Th1-driving capacity. 17 Furthermore, IFN-g could potentially be used to generate mature DC for use in vaccines where a long-lasting memory CD8 + T-cell response is desired. 16 Our previous study demonstrated that IFN-g gene-modified DC produced significantly increased concentrations of IL1b and IL-12p70, and showed enhanced ability to present both MHC class I-and class II-restricted antigens.
On the other hand, IFN-g can directly inhibit the growth of a variety of tumor cells, 19 and it also inhibits angiogenesis through inhibition of VEGF expression by human endometrial stromal cells at both mRNA and protein levels. 20 These results make IFN-g an attractive cytokine for DC-based antiangiogenic immunotherapy of cancer.
In this context, we hypothesized that vaccination with sflk1 and IFN-g fusion gene-transfected DC would elicit more potent antitumor effects than single sflk1-or IFN-gtransfected DC. To test this hypothesis, we constructed a recombinant plasmid harboring sflk1 and IFN-g fusion gene, and studied the antitumor effects after immunization with this fusion gene-modified DC in murine metastasis models. Our data show that immunization with sflk1 gene-modified DC (DC-sflk1) could induce CTL responses to flk1, inhibit tumor cell-induced in vivo angiogensis and reduce tumor metastasis significantly. However, when immunized with sflk1 and IFN-g fusion gene-modified DC (DC-sflk1-IFN-g), more potent CTL responses to flk1 were induced in the mouse model, leading to more significant inhibition of neoangiogenesis and metastasis. Our data provide evidence that the efficacy of DC-based active antiangiogenic immunotherapy can be improved by combination with DC-based cytokine immunotherapy.
Results

Construction and expression of the recombinant plasmids
In order to test our hypothesis that more potent antimetastatic effects would be induced in mice by immunization with sflk1 and IFN-g fusion gene-transfected DC, we constructed recombinant plasmids pcDNA3.1/sflk1, pcDNA3.1/IFN-g, and pcDNA3.1/ sflk1-IFN-g ( Figure 1A ) and transfected COS-7 and DC with plasmid DNA. Protein expression by transiently transfected COS-7 was detected by Western blotting ( Figure 1B) . Protein secretion by transfected DC was determined by ELISA ( Figure 1C ). sflk1 appeared in the lysate of transfected COS-7 cells at about 115 kDa and sflk1-IFN-g fusion protein appeared at 130 kDa, showing the correct size of sflk1 and sflk1-IFN-g fusion protein.
Consistent with previous studies, 18, 21, 22 DC themselves secreted low levels of IFN-g in the presence of LPS; however, pcDNA3.1/IFN-g-transfected DC (DC-IFN-g) and DC-sflk1-IFN-g secreted IFN-g at significantly higher levels. sflk1 was only produced by DC-sflk1 and DCsflk1-IFN-g. These data indicate that DC can efficiently express sflk1 and IFN-g after electroporation with the corresponding plasmid.
Biological activity of the sflk1-IFN-g fusion protein
It is well established that sflk1 can competitively inhibit VEGF binding to membrane flk1 and that IFN-g has antiviral activity. In order to prove the biological functions of the sflk1-IFN-g fusion protein, cell-based ligand-binding competition experiments and antiviral infection experiments were performed. As shown in Figure 2 , culture supernatants of pcDNA3.1/sflk1-transfected and pcDNA3.1/sflk1-IFN-g-transfected COS-7 cells dose-dependently inhibited [ (Figure 2a ), while supernatants of pcDNA3.1-transfected and pcDNA3.1/IFN-g-transfected COS-7 cells did not. Experiments addressing the antiviral activity revealed that culture supernatants of pcDNA3.1/IFN-g-transfected and pcDNA3.1/sflk1-IFN-g-transfected COS-7 cells protected L929 cells from infection with vesicular stomatitis virus (VSV), while supernatants of pcDNA3.1-transfected and pcDNA3.1/ sflk1-transfected COS-7 cells did not. Furthermore, the antiviral activity was abrogated when neutralizing antimouse IFN-g antibody was present (Figure 2b ). Together, these data indicate that the sflk1-IFN-g fusion protein has the biological activities of both sflk1 and IFN-g.
Immunization with DC-sflk1-IFN-g elicits enhanced CTL response to flk1
To examine whether immunization with DC-sflk1-IFN-g would enhance the cellular immune response to flk1, mice were injected intravenously three times with DC, pcDNA3.1-transfected DC (DC-vector), DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or phosphate buffer solution (PBS) at 7-day intervals. At 10 days after the last vaccination, splenocytes were prepared and restimulated in vitro for 9 days with irradiated flk1 + endothelial cell line H5V. Thereafter, CTL activity against H5V and 3LL cells stably transfected with pcDNA3.1/sflk1 (3LL-sflk1) was determined by 4-h 51 Cr-release assay. Figure 3 shows that immunization of mice with DC-sflk1 induced CTL responses to flk1, while immunization with DC, DCvector, DC-IFN-g or injection of PBS did not. Furthermore, CTL activity against H5V (Figure 3a) and 3LL-sflk1 Antiangiogenic cancer immunotherapy with gene-modified DC J Pan et al ( Figure 3b ) was significantly enhanced in splenocytes from mice immunized with DC-sflk1-IFN-g when compared with mice immunized with DC-sflk1 (Po0.01). However, when syngeneic flk1 À cell lines EL-4 and 3LL were used as targets, no significant cytotoxicity was observed (data not shown), implying that this CTL response was specific for flk1. These data suggest that immunization of mice with DC-sflk1 can break selftolerance and induce specific CTL response to flk1; however, this CTL response can be significantly enhanced by immunization with DC-sflk1-IFN-g.
Immunization with DC-sflk1-IFN-g elicits enhanced inhibition of in vivo neoangiogenesis
To test whether a CTL response to flk1 in mice immunized with DC-sflk1 or DC-sflk1-IFN-g would inhibit neoangiogenesis, alginate bead analysis of tumor cell-induced in vivo angiogenesis was performed as described previously. 11, 23 At 10 days after the last vaccination, mice were subcutaneously implanted with alginate beads containing D122.8, a Lewis lung carcinoma cell line. Vascularization of the beads induced by tumor cells was measured by uptake of FITC-dextran 12 days later. Figure 4 shows that neoangiogenesis in mice vaccinated with DC-sflk1 was profoundly inhibited. This inhibition reached about 50% when compared with angiogenesis in mice immunized with DC, DC-vector, DC-IFN-g, or PBS. Although it was reported that IFN-g could inhibit VEGF expression by human endometrial stromal cells at both mRNA and protein levels, 20 no significant inhibition of angiogenesis was observed in mice immunized with such dose of DC-IFN-g. However, inhibition of angiogenesis in mice immunized with DCsflk1-IFN-g was more pronounced when compared with that in mice vaccinated with DC-sflk1 (Po0.01). These data suggest that the additive effect of IFN-g is due to an immunological mechanism enhancing the immune response rather than a direct effect of IFN-g on angiogenesis. 4 L929 cells per well were added into a 96-well plates and incubated at 371C for 24 h. Concentrated culture supernatants of plasmidtransfected COS-7, 100-fold, were added in the presence or absence of 0.1 mg/ml of anti-mouse IFN-g antibody. In all, 25 ml of VSV was added into each well 3 h later. Cells were cultured for another 24 h. A volume of 50 ml of MTT (2 mg/ml) was added into each well 6 h before the end of the culture. After centrifugation at 1000 rpm for 5 min, supernatants were removed. Then, 150 ml of DMSO was added into each well. The optical density was measured at 570 nm. Percent protection of L929 from infection with VSV was calculated. n ¼ 3, *Po0.01 when compared with the group of pcDNA3.1.
Figure 3
Vaccination of mice with DC-sflk1-IFN-g enhances CTL response to flk1. C57BL/6 mice were intravenously injected three times with 1 Â 10 5 DC, DC-vector, DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or 100 ml PBS, respectively, at 7-day intervals. At 10 days after the last immunization, splenocytes from mice were prepared and restimulated in vitro for 9 days with irradiated (4000 rad) H5V at a responder to stimulator ratio of 10:1 in the presence of 50 U/ml IL-2. CTL activity against H5V (a) and 3LL-sflk1 (b) was determined by 4-h 51 Cr-release assay (n ¼ 3, *Po0.01 when compared with that in the groups of PBS, DC, DC-vector, or DC-IFN-g; **Po0.01 when compared with that in the group of DC-sflk1).
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Enhanced antimetastatic effects of DC-sflk1-IFN-g vaccination in murine metastasis models
Next, we examined the antimetastatic effects of DC-sflk1-IFN-g vaccination in a murine metastasis model using the B16 melanoma. Immunized mice were intravenously challenged with B16 melanoma cells 10 days after the last vaccination. As shown in Figure 5 , marked reduction in pulmonary metastases was observed in mice immunized with DC-sflk1 and DC-sflk1-IFN-g (Figure 5a ), while mice immunized with PBS, DC, DC-vector, or DC-IFN-g developed extensive pulmonary metastases. The number of tumor nodules on the lung surface decreased by 81.9% in mice immunized with DC-sflk1 and by 96.8% in mice immunized with DC-sflk1-IFN-g when compared with mice immunized with DC-vector ( Figure 5b ). Furthermore, in agreement with the results of alginate bead analysis of tumor cell-induced angiogenesis, the volume of the tumor nodules on the surface of lungs from mice vaccinated with DC-sflk1 or DC-sflk1-IFN-g was significantly smaller than in other control groups ( Figure  5a ), further supporting the notion that neoangiogenesis is crucial for tumor progression, outgrowth, and metastasis. Most importantly, two of five mice immunized with DC-sflk1-IFN-g were found to be completely tumor-free on the surface of the lungs, which was confirmed not only by visual examination but also by histological analysis of the lungs (Figure 5c ). To confirm the antimetastatic effects in another tumor model, a murine metastasis model of 3LL Lewis lung carcinoma was employed. Our data showed again that vaccination of mice with DCsflk1 could significantly inhibit pulmonary metastases, and improved anti-metastatic effects were obtained when mice were vaccinated with DC-sflk1-IFN-g ( Figure 6 ).
These data demonstrate that, although immunization with sflk1-encoding cDNA transfected DC is effective in antiangiogenic therapy for cancer, the therapeutic efficacy of this strategy can be improved by combination with DC-based cytokine immunotherapy.
CD8
+ T cells are mainly responsible for the antimetastatic effects induced by DC-sflk1 or DC-sflk1-IFN-g vaccination To determine which T-cell subset (ie, CD4 + , CD8 + or both) was responsible for the antimetastatic effects, in vivo T-cell subset depletion was performed in mice vaccinated with DC-sflk1 or DC-sflk1-IFN-g in the B16 melanoma metastasis model. As shown in Figure 7 , the antimetastatic effects of vaccination with either DC-sflk1 Figure 5 Immunization of mice with DC-sflk1-IFN-g elicits improved antimetastatic effects in B16 melanoma metastatic model. C57BL/6 mice were immunized three times with 1 Â 10 5 of DC, DC-vector, DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or 100 ml of PBS. At 10 days after the last immunization, mice were intravenously challenged with 1 Â 10 6 B16 melanoma cells. After 28 days, mice were killed and photographs of one representative tumor-bearing lung in each group was made (a). Tumor nodules on the surface of lung were counted (b), and histological examination was performed (c); HE staining, original magnification: Â 100). n ¼ 5-6, *Po0.01 when compared with that in the groups of PBS, DC, DC-vector, or DC-IFN-g; **Po0.01 compared with that in the group of DC-sflk1. 
Discussion
Recent studies have demonstrated that active immunization of mice with DC-based vaccine against angiogenesis can stimulate antimetastatic effects by interfering with the tumor-induced neoangiogenesis. 11, 12 The present study tested our hypothesis that immunization of mice with sflk1 and IFN-g fusion gene-transfected DC would elicit more potent antiangiogenic effects and inhibit tumor metastasis more potently than single genetransfected DC. Our data clearly show that although vaccination with DC-sflk1 can elicit significant antimetastatic effects in murine models, improved therapeutic effects were achieved in mice immunized with DC-sflk1-IFN-g. As flk1 is strictly expressed in proliferating endothelial cells, 2 but not in B16 melanoma cells and 3LL Lewis lung carcinoma cells (data not shown), it is conceivable that the antitumor effects observed were caused indirectly by interference with the tumor cellinduced vascularization. This is consistent with the observed results of CTL response to flk1 and tumor cell-induced in vivo angiogenesis.
DC are crucial antigen-presenting cells that activate T-cell-dependent immune responses. Enhancing their function is a central goal of new therapeutic vaccine strategies. 16, 24 In the past, several approaches have been used to improve the potency of DC-based vaccines. For example, incorporating GM-CSF that induces DC differentiation into vaccines, 24, 25 targeting antigen to specific receptors on DC by using antigen-GM-CSF fusion proteins or immunoglobulin Fc region-antigen fusion proteins can potentiate the immunogenicity of the antigen and induce effective immune responses. In consideration of the roles of heat-shock protein in antigen processing, antigens are also fused with some members of the heat-shock protein family that enter DC through CD91 (a2-macroglobulin receptor), hereby substantially enhancing the immunogenicity of the antigen by activating DC and targeting them into the MHC processing pathway. 26, 27 On the other hand, it was reported that the Th1-or Th2-inducing function is not an intrinsic attribute of DC and the development of Th1-or Th2-driving capacity of DC requires environmental instructions. 17, [28] [29] [30] In serum-free conditions, CD14 + monocytes rapidly differentiate, in the presence of exogenous IFN-g and in response to LPS, into CD83 + DC with the increased capacity to stimulate alloreactive T cells and secrete IL-12. 30 After IFN-g treatment, the expression by CD11c + DC of MHC class II and maturation-associated molecules such as CD80, CD86, and CD83 increased and more IL-12 was secreted, which allowed DC to increase Th1 responses by alloreactive T cells. 28 Moreover, DC derived from IFN-g transgenic mice showed significantly increased ability to stimulate allogeneic and antigen-specific T lymphocytes, and produced more IL-12 to induce Th1 cell responses when compared with DC from the wild-type mice. 31 Our previous study demonstrated that IFN-g gene-modified DC secreted more IL-12p70 and showed increased capacity to present both MHC class I-and II-restricted antigen to T cells. 18 In order to improve the therapeutic efficacy of DC-based antiangiogenic immunotherapy for cancer, we immunized mice with sflk1 and IFN-g fusion gene-modified DC. In this case, sflk1 produced by the gene-modified DC can not only be presented to CD8 + T cells through the MHC class I pathway, but also be presented to CD4 + T cells in a MHC class II context. IFN-g can act on DC in an autocrine manner as well as on the primary immune effector cells in the immunological synapse in a paracrine manner, thus augmenting systemic immune response to flk1. This may explain why immunization with DC-sflk1-IFN-g can elicit more potent CTL response to flk1 than does immunization with DC-sflk1. Lewis lung carcinoma metastatic model. C57BL/6 mice were immunized three times with 10 5 of DC, DC-vector, DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or 100 ml of PBS. At 10 days after the last immunization, mice were challenged with an intrafootpad injection of 2 Â 10 5 3LL Lewis lung carcinoma cells. When tumors reached B6 mm in diameter, the tumorbearing leg was surgically amputated. Mice were killed based on the metastatic death in the control groups. Tumor load was evaluated by counting tumor nodules on the lung surface. n ¼ 8-10, *Po0.01 when compared with that in the groups of PBS, DC, DC-vector, or DC-IFN-g; **Po0.01 when compared with that in the group of DC-sflk1.
Figure 7 CD8
+ T cells are mainly responsible for the antimetastatic effects of DC-sflk1 or DC-sflk1-IFN-g vaccination. C57BL/6 mice were intraperitoneally injected with anti-CD4, anti-CD8, or mock control antibody on the fourth and first days before vaccination of DC-sflk1 or DC-sflk1-IFN-g, and another three injections of antibodies were given at 3-day intervals. In an additional control group that received injection of DC-vector, mice were not treated with antibodies. At 10 days after the last immunization, mice were challenged with B16 melanoma cells. After 28 days, mice were killed and tumor load was evaluated by counting the tumor nodules on lung surface. n ¼ 8, *Po0.01 when compared with the corresponding group.
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Although it was reported that IFN-g itself could inhibit VEGF expression by endometrial stromal cells 20 and has direct antiproliferative effects on some tumor cell lines, 19 in our animal models, immunization of mice with such dose of DC-IFN-g did not show any significant inhibitory effects on tumor cell-induced angiogenesis and metastasis, suggesting that the enhanced antimetastatic effect of DC-sflk1-IFN-g vaccination was not the direct result of growth inhibition of tumor cells by IFN-g secreted by DC-sflk1-IFN-g. Furthermore, our in vivo T-cell subset depletion experiment showed that the antimetastatic effect induced by DC-sflk1 or DC-sflk1-IFN-g vaccination was CD8
+ T cell dependent. These data further support the concept that the improved antimetastatic effects of DC-sflk1-IFN-g vaccination result from the enhanced inhibition of tumor-induced angiogenesis through induction of augmented CTL response to flk1.
IFN-g can induce, in the presence of LPS, coordinated expression of IL-15Ra and IL-15 by monocytes and DC. The cell surface IL-15Ra generated by DC can present IL-15 in trans to neighboring CD8 + T cells, thereby facilitating the long survival of memory CD8 + T cells which is crucial for a sustained immune response to a vaccine. 32 Therefore, the impact of DC-sflk1-IFN-g vaccination on the persistence of CTL response to flk1 deserves further investigation, and the influence of this antiangiogenic strategy on angiogenesis occuring under physiological conditions, such as pregnancy, needs to be evaluated very carefully in future.
In summary, antiangiogenic immunotherapy for cancer has several merits, especially it takes the advantage of targeting the antigens expressed on the endothelial cells that are genetically stable, thus avoiding the problems of tumor-targeting immunotherapy, such as genetic instability of tumor cells and downregulation of MHC class I and II molecules by which tumor cells escape immunosurveillance. In the present study, we used a DC-based active antiangiogenic immunotherapy by combining antiangiogenic therapy with cytokine immunotherapy to improve the antimetastatic efficacy. On the basis of vaccination with sflk1-or sflk1-IFN-g-encoding cDNA-transfected DC, our data extend the notion that active DC-based antiangiogenic immunotherapy for cancer is effective, and show that the efficacy of this strategy can be further improved by combined antiangiogenic and cytokine immunotherapy. , and 1 mg of total RNA was reverse transcribed using a Reverse Transcription kit (Amersham Biosciences Europe GmbH, Freiburg, Germany) according to the manufacturer's instructions. cDNA was amplified by PCR using specific primers for sflk1. Sense: 5 0 -CG GGA TCC ATG GAG AGC AAG GCG CTG-3 0 ; antisense: 5 0 -G GAA TTC TCA TTC CAA GTT GGT CTT TTC-3 0 , with an expected product of 2304 bp including cDNA encoding sflk1, BamHI (5 0 ) and EcoRI (3 0 ) restriction sites and the artificial termination codon. After TA cloning and sequencing, the sflk1-encoding fragment was cloned into pcDNA3.1(+) between BamHI and EcoRI restriction sites.
Materials and methods
Mice and cell lines
Construction of pcDNA3.1/IFN-g. Total RNA was extracted with RNeasy Mini Kit from murine splenocytes which had been stimulated by ConA (5 mg/ml) for 48 h. In all, 1 mg total RNA was reverse transcribed. cDNA was amplified by PCR using specific primers for IFN-g. Sense:
0 with an expected product of 486 bp, including cDNA encoding IFN-g, EcoRI and XbaI restriction sites. After TA cloning and sequencing, the IFN-gencoding fragment was cloned into EcoRI and XbaI restriction sites of the pcDNA3.1 (+) vector.
Construction of pcDNA3.1/sflk1-IFN-g. cDNA of sflk1 (bases 208-2493) which lacks the artificial termination codon was amplified by PCR using the above-mentioned sense primer and a different antisense primer (5 0 -G GAA TTC TTC CAA GTT GGT CTT TTC-3 0 ), and inserted into the BamHI and EcoRI restriction sites of pcDNA3.1/IFNg to form the recombinant plasmid harboring sflk1 and IFN-g fusion gene.
Transfection of COS-7 with plasmid COS-7 cells were transfected with the corresponding plasmid by Lipofectamine TM 2000 (Invitrogen) according to the instruction of the manufacturer. Supernatants were collected 48 h later and used for identification of biological activity of sflk1 and IFN-g. Cells were harvested for preparation of cytoplasmic protein by NE-PER TM Nuclear and Cytoplasmic Extraction Reagents (Pierce).
Western blotting
Protein expression of sflk1-IFN-g was demonstrated by Western blotting of transfected COS-7 cells. Blots were probed with anti-mouse VEGFR2 extracellular domain (goat IgG; R&D Systems, Inc.) and then were incubated at room temperature for 1 h with 1:5000 diluted HRPconjugated anti-goat IgG. Proteins were visualized using SuperSignal West Femto Maximum Sensitivity Substrates (Pierce). 
Antiviral activity assay
To examine the antiviral activity of sflk1-IFN-g fusion protein, L929 cells (2 Â 10 4 per well) were added into a 96-well plates and incubated at 371C for 24 h. Concentrated culture supernatants, 100-fold of plasmid-transfected COS-7 were added. In the neutralization group, 0.1 mg/ml of anti-mouse IFN-g antibody (R&D Sysems, Inc.) was added together with the supernatant. After 3 h, 25 ml of VSV was added into each well. Cells were cultured for another 24 h. At 6 h before the end of the culture, 50 ml of MTT (2 mg/ml) was added into each well. After centrifugation at 1000 rpm for 5 min, supernatants were removed. Then, 150 ml of DMSO was added into each well. The optical density was measured at 570 nm on an ELISA reader (ELx800 universal microplate reader, Bio-Tec instruments, Inc., USA). Results are expressed as percent protection of L929 from infection of VSV.
Preparation of DC
DC were prepared from bone marrow progenitor cells as described previously. 33 Briefly, erythrocyte-depleted bone marrow cells derived from C57BL/6 mice were resuspended at a concentration of 2 Â 10 6 /ml in RPMI 1640 (Invitrogen) complete medium (10% heat-inactivated FCS) supplemented with murine GM-CSF (30 ng/ ml; PeproTech, London, UK) and IL-4 (20 ng/ml; PeproTech, London, UK), cultured in six-well tissue culture plates (Nunc, Denmark). After 3 days, nonadherent cells were removed and the adherent cells were replenished with fresh RPMI 1640 complete medium containing GM-CSF and IL-4. The nonadherent and loosely adherent cells were harvested as DC after another 3 days. These DC (day-6 DC) expressed CD80, CD86, CD40, and MHC class II molecules when assessed by flow cytometric analysis (data not shown).
Electroporation of DC with plasmid DNA Electroporation was performed as described previously 34 with some modifications. Briefly, day-6 DC were harvested, washed two times in RPMI 1640 medium, and resuspended in RPMI 1640 at 2 Â 10 7 cells/ml. 2 Â 10 6 cells were electroporated in 2-mm cuvettes at 240V for 16 ms with 20 mg plasmid DNA using Gene Pulser II (BioRad). Subsequent to electroporation, DC were immediately transferred to six-well culture plates containing 3 ml of RPMI 1640 complete medium supplemented with GM-CSF and IL-4, as well as 100 ng/ml of LPS (Sigma) and incubated at 371C, 5% CO 2 for 48 h. Supernatants were harvested for measurement of sflk1 and IFN-g secretion by ELISA. DC were washed three times and resuspended at 1 Â 10 6 /ml PBS for injection.
Measurement of sflk1 and IFN-g by ELISA
Secretion of sflk1 and IFN-g by gene-transfected DC was detected by the sandwich ELISA technique (R&D Systems GmbH, Germany), following the instructions of the manufacturer.
Immunization of mice with gene-modified DC
For immunization, C57BL/6 mice were intravenously injected three times with 1 Â 10 5 cells per mouse of DC, DC-vector, DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or PBS (100 ml) at 7-day intervals. At 10 days after the last immunization, the immunized mice were subjected to assessment of CTL response to flk1, alginate bead analysis of tumor cell-induced angiogenesis, or observation of the antimetastatic effects in B16 melanoma and 3LL Lewis lung carcinoma metastasis models.
Induction of CTL and cytotoxicity assay
CTL responses were assessed as described previously 33, 35 with minor modifications. Briefly, 10 days after the last immunization, erythrocyte-depleted splenocytes from mice (three mice in each group) were prepared and restimulated for 9 days with irradiated (4000 rad) flk1-expressing cell line H5V (at a responder to stimulator ratio of 10:1) in the presence of 50 U/ml of murine IL-2 (PeproTech, London, UK) in RPMI 1640 with 10% FCS. CTL activity was determined by standard 4-h 51 Crrelease assay against flk1 + endothelial cell line H5V, 3LL-sflk1, and flk1 À cell lines EL-4 and 3LL that served as the negative control targets. Specific cytotoxic activity was calculated using the formula: % specific release ¼ ðexperimental release À spontaneous releaseÞ=ðmaximum release À spontaneous releaseÞÂ100:
Data are expressed as mean7s.d.
Alginate bead analysis of angiogenesis
Alginate bead analysis of tumor cell-induced in vivo angiogenesis was performed as described previously.
11,23
Briefly, Lewis lung carcinoma cells D122.8 were suspended in 1.5% sodium alginate and added drop by drop into a swirling 371C solution of 250 mM calcium chloride. Alginate beads were formed containing 5 Â 10 4 tumor cells. Four beads per mouse were implanted subcutaneously through an incision made on the dorsal side under anesthetization. Incisions were surgically closed. After 12 days, mice were intravenously injected with 100 ml of FITC-dextran solution (20 mg/ml). Mice were killed 20 min later, alginate beads were removed, and incubated overnight at room temperature in 1 ml of 1 mM Tris-HCl (pH 8.0). The beads were ground with a hand-held mixer and an additional 1 ml of 1 mM TrisHCl was added. Samples were vortexed and centrifuged for 5 min at 1500 rpm. Fluorescence of the sample supernatants was measured on a fluorescence spectro- 
B16 melanoma metastasis model
Mice were intravenously injected three times with DC, DC-vector, DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or PBS. At 10 days after the last immunization, mice were intravenously injected with 1 Â 10 6 B16 melanoma cells and were killed 28 days later. Tumor load was evaluated by counting tumor nodules on the lung surface.
3LL Lewis lung carcinoma metastasis model
Mice (8-10 in each group) were intravenously injected three times with DC, DC-vector, DC-sflk1, DC-IFN-g, DC-sflk1-IFN-g, or PBS at 7-day intervals. At 10 days after the last immunization, mice were challenged with an intrafootpad injection of 2 Â 10 5 of 3LL tumor cells. When the tumor reached B6 mm in diameter, the tumorbearing leg was surgically amputated. Mice were killed based on the metastatic death in the control groups. Tumor load was evaluated by counting the tumor nodules on the surface of the lung.
In vivo depletion of T-cell subset
Monoclonal antibodies GK1.5 anti-CD4 (TIB 207, ATCC) and 2,43 anti-CD8 (TIB 210, ATCC) were used to deplete CD4 + T cells and CD8 + T cells, respectively. Antibodies (0.1 mg per injection) were injected intraperitoneally in 0.1 ml of PBS into each mouse on the fourth and first day before vaccination of gene-modified DC, and another three injections of antibodies were given at 3-day intervals. Normal rat IgG (Sigma) was used as the mock control. Depletion of T-cell subsets was monitored by FACS, which showed more than 90% specific depletion in splenocytes (data not shown).
Histological examination
Lung samples from B16 melanoma metastasis murine models with different treatment were fixed in 10% formalin, embedded in paraffin, and sectioned at 5 mm. Hematoxylin and eosin staining was performed.
Statistics
Data were analyzed by Student's t-test. A P-value o0.05 was considered to be statistically significant.
